医疗保险公司Molina Healthcare Inc近日宣布，其价值约10亿美元的Medicare Advantage处方药计划（MAPD）产品已不再符合公司最新战略方向。该公司决定将业务重心全面转向规模达50亿美元的双资格医疗保险业务，专为同时符合Medicare和Medicaid资格的群体提供服务。
这一战略调整标志着Molina Healthcare将资源集中于增长潜力更大的核心领域。双资格医保业务作为公司优势板块，年规模达50亿美元，而MAPD产品线规模约为10亿美元。通过剥离非核心业务，公司有望优化资源配置，提升在专业医保细分市场的竞争力。
分析师指出，此举符合医疗保险公司专业化运营趋势，或将强化Molina Healthcare在政府医保项目中的差异化优势。随着美国医保政策持续演变，专注双资格人群这一战略定位可能为公司带来更可持续的增长动能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.